Marta Garcia Daneshvar

Marta Garcia Daneshvar is an intellectual property lawyer at Finnegan, Henderson, Farabow, Garrett & Dunner, based in Boston, MA. Her practice centers on patent litigation, particularly within the life sciences, biotechnology, and pharmaceutical sectors. This specialization is evidenced by her representation in a high-stakes gene therapy patent dispute and her role as a presenter at Finnegan's Life Sciences Workshops covering updates in pharmaceutical and biotechnology IP law. She also co-authors "D. Mass. Patent Litigation Update" articles, demonstrating familiarity with broader patent litigation trends, including trade secrets and patent eligibility challenges.

Garcia Daneshvar primarily represents defendants in patent litigation, with her only tracked appearance being on the defendant side as lead counsel. In the notable case of Genzyme Corporation v. Novartis Gene Therapies, Inc., she served as lead counsel for Novartis Gene Therapies, Inc. and Novartis Pharmaceuticals Corporation. This case, involving six patents related to recombinant adeno-associated virus (AAV) vectors for gene therapy, concluded with a dismissal with prejudice via a joint stipulation, with each party bearing its own costs.

Her involvement extends to discussions and analyses of Patent Trial and Appeal Board (PTAB) proceedings, as indicated by her participation in seminars addressing topics such as IPR estoppel and USPTO rulemaking proposals. This suggests a command of post-grant review strategies in addition to district court litigation.

Marta Garcia Daneshvar is admitted to the State Bar of California (2017) and earned her law degree from Stanford University Law School.